170 related articles for article (PubMed ID: 38168198)
1. Artificial intelligence-based morphometric signature to identify ductal carcinoma in situ with low risk of progression to invasive breast cancer.
Sobral-Leite M; Castillo S; Vonk S; Melillo X; Lam N; de Bruijn B; Hagos Y; Sanders J; Almekinders M; Visser L; Groen E; Kristel P; Ercan C; Azarang L; Yuan Y; ; Menezes R; Lips E; Wesseling J
Res Sq; 2023 Dec; ():. PubMed ID: 38168198
[TBL] [Abstract][Full Text] [Related]
2. Breast adipocyte size associates with ipsilateral invasive breast cancer risk after ductal carcinoma in situ.
Almekinders MMM; Schaapveld M; Thijssen B; Visser LL; Bismeijer T; Sanders J; Isnaldi E; Hofland I; Mertz M; Wessels LFA; Broeks A; Hooijberg E; Zwart W; Lips EH; ; Desmedt C; Wesseling J
NPJ Breast Cancer; 2021 Mar; 7(1):31. PubMed ID: 33753731
[TBL] [Abstract][Full Text] [Related]
3. Clinicopathological Risk Factors for an Invasive Breast Cancer Recurrence after Ductal Carcinoma
Visser LL; Elshof LE; Schaapveld M; van de Vijver K; Groen EJ; Almekinders MM; Bierman C; van Leeuwen FE; Rutgers EJ; Schmidt MK; Lips EH; Wesseling J
Clin Cancer Res; 2018 Aug; 24(15):3593-3601. PubMed ID: 29685879
[No Abstract] [Full Text] [Related]
4. The effects of contemporary treatment of DCIS on the risk of developing an ipsilateral invasive Breast cancer (iIBC) in the Dutch population.
Alaeikhanehshir S; Schmitz RSJM; van den Belt-Dusebout AW; van Duijnhoven FH; Verschuur E; van Seijen M; Schaapveld M; Lips EH; Wesseling J;
Breast Cancer Res Treat; 2024 Feb; 204(1):61-68. PubMed ID: 37964135
[TBL] [Abstract][Full Text] [Related]
5. Comprehensive multiplexed immune profiling of the ductal carcinoma in situ immune microenvironment regarding subsequent ipsilateral invasive breast cancer risk.
Almekinders MM; Bismeijer T; Kumar T; Yang F; Thijssen B; van der Linden R; van Rooijen C; Vonk S; Sun B; Parra Cuentas ER; Wistuba II; Krishnamurthy S; Visser LL; Seignette IM; Hofland I; Sanders J; Broeks A; Love JK; Menegaz B; Wessels L; Thompson AM; de Visser KE; Hooijberg E; Lips E; Futreal A; Wesseling J;
Br J Cancer; 2022 Oct; 127(7):1201-1213. PubMed ID: 35768550
[TBL] [Abstract][Full Text] [Related]
6. Long-term risk of subsequent ipsilateral lesions after surgery with or without radiotherapy for ductal carcinoma in situ of the breast.
van Seijen M; Lips EH; Fu L; Giardiello D; van Duijnhoven F; de Munck L; Elshof LE; Thompson A; Sawyer E; Ryser MD; Hwang ES; Schmidt MK; Elkhuizen PHM; ; Wesseling J; Schaapveld M
Br J Cancer; 2021 Nov; 125(10):1443-1449. PubMed ID: 34408284
[TBL] [Abstract][Full Text] [Related]
7. Treating (low-risk) DCIS patients: What can we learn from real-world cancer registry evidence?
Byng D; Retèl VP; Schaapveld M; Wesseling J; van Harten WH;
Breast Cancer Res Treat; 2021 May; 187(1):187-196. PubMed ID: 33389397
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of histopathological DCIS features in a large-scale international interrater reliability study.
Groen EJ; Hudecek J; Mulder L; van Seijen M; Almekinders MM; Alexov S; Kovács A; Ryska A; Varga Z; Andreu Navarro FJ; Bianchi S; Vreuls W; Balslev E; Boot MV; Kulka J; Chmielik E; Barbé E; de Rooij MJ; Vos W; Farkas A; Leeuwis-Fedorovich NE; Regitnig P; Westenend PJ; Kooreman LFS; Quinn C; Floris G; Cserni G; van Diest PJ; Lips EH; Schaapveld M; Wesseling J;
Breast Cancer Res Treat; 2020 Oct; 183(3):759-770. PubMed ID: 32734520
[TBL] [Abstract][Full Text] [Related]
9. Subsequent risk of ipsilateral and contralateral invasive breast cancer after treatment for ductal carcinoma in situ: incidence and the effect of radiotherapy in a population-based cohort of 10,090 women.
Elshof LE; Schaapveld M; Schmidt MK; Rutgers EJ; van Leeuwen FE; Wesseling J
Breast Cancer Res Treat; 2016 Oct; 159(3):553-63. PubMed ID: 27624164
[TBL] [Abstract][Full Text] [Related]
10. Ductal Carcinoma In Situ - Quo Vadis?
Peltecu G
Chirurgia (Bucur); 2021 Dec; 116(5 Suppl):S5-S6. PubMed ID: 34967322
[TBL] [Abstract][Full Text] [Related]
11. Biomarker expression and risk of subsequent tumors after initial ductal carcinoma in situ diagnosis.
Kerlikowske K; Molinaro AM; Gauthier ML; Berman HK; Waldman F; Bennington J; Sanchez H; Jimenez C; Stewart K; Chew K; Ljung BM; Tlsty TD
J Natl Cancer Inst; 2010 May; 102(9):627-37. PubMed ID: 20427430
[TBL] [Abstract][Full Text] [Related]
12. The prognostic role of HER2 expression in ductal breast carcinoma in situ (DCIS); a population-based cohort study.
Borgquist S; Zhou W; Jirström K; Amini RM; Sollie T; Sørlie T; Blomqvist C; Butt S; Wärnberg F
BMC Cancer; 2015 Jun; 15():468. PubMed ID: 26062614
[TBL] [Abstract][Full Text] [Related]
13. A whole slide image-based machine learning approach to predict ductal carcinoma in situ (DCIS) recurrence risk.
Klimov S; Miligy IM; Gertych A; Jiang Y; Toss MS; Rida P; Ellis IO; Green A; Krishnamurti U; Rakha EA; Aneja R
Breast Cancer Res; 2019 Jul; 21(1):83. PubMed ID: 31358020
[TBL] [Abstract][Full Text] [Related]
14. Management and 5-year outcomes in 9938 women with screen-detected ductal carcinoma in situ: the UK Sloane Project.
Thompson AM; Clements K; Cheung S; Pinder SE; Lawrence G; Sawyer E; Kearins O; Ball GR; Tomlinson I; Hanby A; Thomas JSJ; Maxwell AJ; Wallis MG; Dodwell DJ;
Eur J Cancer; 2018 Sep; 101():210-219. PubMed ID: 30092498
[TBL] [Abstract][Full Text] [Related]
15. Effect of quantitative nuclear image features on recurrence of Ductal Carcinoma In Situ (DCIS) of the breast.
Axelrod DE; Miller NA; Lickley HL; Qian J; Christens-Barry WA; Yuan Y; Fu Y; Chapman JA
Cancer Inform; 2008; 6():99-109. PubMed ID: 18779878
[TBL] [Abstract][Full Text] [Related]
16. Finding the balance between over- and under-treatment of ductal carcinoma in situ (DCIS).
Groen EJ; Elshof LE; Visser LL; Rutgers EJT; Winter-Warnars HAO; Lips EH; Wesseling J
Breast; 2017 Feb; 31():274-283. PubMed ID: 27671693
[TBL] [Abstract][Full Text] [Related]
17. HER2/neu and Ki-67 expression predict non-invasive recurrence following breast-conserving therapy for ductal carcinoma in situ.
Rakovitch E; Nofech-Mozes S; Hanna W; Narod S; Thiruchelvam D; Saskin R; Spayne J; Taylor C; Paszat L
Br J Cancer; 2012 Mar; 106(6):1160-5. PubMed ID: 22361634
[TBL] [Abstract][Full Text] [Related]
18. HER2 overexpression in ductal carcinoma in situ is associated with ipsilateral breast cancer recurrence after conservative surgery.
Gong DH; Ge JY; Chen YY; Ding KF; Yu KD
Transl Cancer Res; 2020 Jun; 9(6):3787-3793. PubMed ID: 35117746
[TBL] [Abstract][Full Text] [Related]
19. Can dedicated breast PET help to reduce overdiagnosis and overtreatment by differentiating between indolent and potentially aggressive ductal carcinoma in situ?
Graña-López L; Herranz M; Domínguez-Prado I; Argibay S; Villares Á; Vázquez-Caruncho M
Eur Radiol; 2020 Jan; 30(1):514-522. PubMed ID: 31375867
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
